Back to Newsroom

New FDA Breakthrough Therapy Designation Warmly Welcomed

It has been just over a year since the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. Contained within the act is a breakthrough therapy (BT) designation, intended to expedite the development and review of drug candidates, which has certainly found favor among biopharmaceutical companies.